Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cetrorelix 78+78 · 1 trial · 1 indication
IPSS score of BPH symptoms based on a patient questionnaire assessing 7 items (incomplete voiding, frequency, intermittency, urgency, weak stream, hesitancy, nocturia) on a scale from 0 (best) to 5 (worst); total overall score range: 0 points (best) to 35 points (worst)
| Arm | Type | Description |
|---|---|---|
| Cetrorelix 78+78 | EXPERIMENTAL | - |
| Cetrorelix 78 + Placebo | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cetrorelix 78+78 | DRUG | Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg) |
| Cetrorelix 78 + Placebo | DRUG | Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28 |
| Placebo | OTHER | Placebo on Week 0, Week 2, Week 26 and Week 28 |
Inclusion Criteria: * Benign Prostatic Hyperplasia, based on medical history * Voiding symptoms Exclusion Criteria: * Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder * Major organ dysfunction * Eczema (atopic dermatitis) treated during the last 6 months * C...
Cetrorelix 78+78 is an investigational small molecule being developed for the treatment of benign prostatic hypertrophy (BPH), a condition also known as enlarged prostate. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Cetrorelix 78+78 is being developed by COSCIENS Biopharma Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol CSCI. The company is conducting clinical trials to evaluate the drug's safety and efficacy for benign prostatic hypertrophy.
Cetrorelix 78+78 is in Phase 3 clinical development for benign prostatic hypertrophy. It is an investigational drug, meaning it has not yet been approved by regulatory agencies and is still undergoing clinical trials to assess its safety and effectiveness.
Cetrorelix 78+78 has one completed Phase 3 clinical trial registered under NCT00663858, titled 'Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)'. This randomized, double-blind, placebo-controlled trial enrolled 420 male participants aged 50 years and older across multiple European countries.
Yes, Cetrorelix 78+78 is also known as Cetrorelix pamoate. The clinical trial NCT00663858 refers to the drug as 'Cetrorelix Pamoate', and it is being studied for the treatment of symptomatic benign prostatic hypertrophy.